Business
Annual Report and Accounts and Notice of AGM
Annual Report and Accounts and Notice of AGM.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 4753J Angle PLC 09 September 2016 \n\n \n \n\n\n\n\nFor immediate release\n\n\n 9 September 2016\n\n\n\n\n \nANGLE plc \n(\"ANGLE\" or \"the Company\")\n \nAnnual Report and Accounts and Notice of AGM\n \n \nANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, announces that its Annual Report and Accounts for the year ended 30 April 2016 and its Notice of Annual General Meeting (AGM) have been distributed to shareholders.\n \nThe AGM will be held at 2:00pm on Tuesday 4 October 2016 at the Surrey Technology Centre, 40 Occam Road, the Surrey Research Park, Guildford, GU2 7YG.\n \nThe Company's Annual Report and Accounts, which incorporates the Notice of AGM, are available on the Company's website http://www.angleplc.com/investor-information/financial-reports/.\n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n01483 685830\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n \n\n\n\n\n\n\n\nCenkos Securities\nStephen Keys (Nominated adviser)\nRussell Kerr, Oliver Baxendale (Sales) \n \n\n\n020 7397 8900\n\n\n\n\nWG Partners\nDavid Wilson\nClaes Spång\n \n\n\n020 3705 9330\n\n\n\n\nFTI Consulting\nSimon Conway, Mo Noonan, Stephanie Cuthbert\nKimberley Ha (US) \n\n\n \n020 3727 1000\n001 212 850 5612\n\n\n\n\n \n \nFor Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/\n \n \nNotes for editors\n \nAbout ANGLE plc www.angleplc.com \n \nANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.\n \nANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, China and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compre...